{
  "id": 13678439,
  "title": "Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.",
  "url": "https://urgent.news/2026/10/11/grail-stock-hit-a-12-month-high-after-its-fda-panel-win-but-heres-the",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-11T08:11:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/11/grail-stock-hit-12-month-high-fda-panel-win-risk/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": null,
  "summary": "Grail (NASDAQ: GRAL) stock surged to a 12-month high following its FDA panel win, but investors should be wary of certain risks. The company's Molecular and Clinical Genetics Devices Panel voted in favor of Galleri's safety, benefit, and effectiveness, paving the way for FDA marketing approval. While this is a significant milestone, another crucial factor to consider is Grail's pricing strategy. The company's binary event of FDA approval and medical insurer coverage has garnered most of the attention, but the pricing of its multi-cancer early detection test could impact its long-term success and investor returns.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.",
        "url": "https://urgent.news/2026/10/11/grail-stock-hit-a-12-month-high-after-its-fda-panel-win-but-heres-the-13686352",
        "published": "2026-10-11T08:31:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}